First human test for new drug targeting devastating genetic immune diseases
Disease control
Recruiting now
This is a very early study to check the safety of a new drug called IMSB301 in people with rare, lifelong genetic conditions known as type 1 interferonopathies. The study will enroll about 6 patients, aged 12 and up, who have specific genetic mutations. Researchers will give part…
Phase: PHASE1 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC